A phase 2 study of vorinostat in acute myeloid leukemia - Wikidata - awgldk - TriplyDB

A phase 2 study of vorinostat in acute myeloid leukemia

A phase 2 study of vorinostat in acute myeloid leukemia

http://www.wikidata.org/entity/Q24643266

about

Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents Epigenetic regulators and their impact on therapy in acute myeloid leukemia Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Core Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic Opportunities Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer Exploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation Assays Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells Panobinostat in lymphoid and myeloid malignancies.Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia.Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives.Molecular therapy for acute myeloid leukaemia.Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.Genetic abnormalities and challenges in the treatment of acute myeloid leukemia.The gene signature in CCAAT-enhancer-binding protein α dysfunctional acute myeloid leukemia predicts responsiveness to histone deacetylase inhibitors.Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects.A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia.Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells.Neurotoxicity of biologically targeted agents in pediatric cancer trials The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia Acute Myeloid Leukemia: Advancements in Diagnosis and Treatment.Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia.Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.Romidepsin: a novel histone deacetylase inhibitor for cancer.Toxicological and metabolic considerations for histone deacetylase inhibitors.Novel therapies for children with acute myeloid leukaemia.Novel drugs for older patients with acute myeloid leukemia.Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.The safety of treatment options for elderly people with acute myeloid leukemia.Panobinostat for the treatment of acute myelogenous leukemia.Chemotherapy Options for Poor Responders to Neoadjuvant Chemotherapy for Orbital Granulocytic Sarcoma.Effects of suberoylanilide hydroxamic acid (SAHA) combined with paclitaxel (PTX) on paclitaxel-resistant ovarian cancer cells and insights into the underlying mechanisms.Overview of Histone Deacetylase Inhibitors in Haematological Malignancies.Treatment of Elderly Patients With Acute Myeloid Leukemia.Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia.A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.The DAC system and associations with acute leukemias and myelodysplastic syndromes.

P2860

Q24633763-B6AFCD1C-A41F-4E41-A38A-AD0B496340FB Q26765402-CB973E38-0B38-449E-B20E-877B9E98FE2A Q26770391-288B9B05-D2D4-456C-8710-9ED5D63913B0 Q26863756-966E75F8-64F6-4D34-ACFD-58C40D709967 Q28538435-B2859D1C-BA31-429A-905D-4DA680B557C4 Q28550025-E8EB9956-4FED-45BF-AD35-8C5DC9D6C47B Q28743758-76C44903-60CD-482F-8A91-E885470D1A42 Q33408889-7744797B-2A0D-4A00-BF0B-85FA2983E39F Q33424306-DBA90DE8-927B-425F-95D7-9253126A0316 Q33437309-682047FB-B8ED-446E-A630-14C474F9958B Q33807542-0E32B43B-7DFA-4C7D-AF20-DDE5F02F0EC3 Q33925672-05AF3D60-D3CF-4F45-B825-D0C47EA657A8 Q34488424-91AE1D22-FC68-4F4B-9F87-FF1991598E4E Q34631111-49B40C05-DC24-465A-AB46-074849A105FD Q35026864-3F907D15-E4EE-40E1-93D5-6E76B6A73511 Q35546759-47FADB4C-640C-4FBE-B89B-EAB544F1D64B Q35939690-CAC03036-3391-41D2-B8E8-BA1E4F9D1A5B Q36395421-C496DD2B-4974-4F19-8CAF-ADCD2696A9A6 Q36400882-D5EC6960-D82C-4766-A67A-C3878170458C Q36766221-40464477-BF96-4A3F-9364-2FEE2151A012 Q37153361-E00B16DB-8C2F-4640-A924-B243103E15CC Q37615574-9C46E4F2-49D7-4E00-9772-AE4905D9525C Q37701599-318208F7-C712-4CC2-BFBC-B3C3DC2AC30C Q37813392-F3EF0A0F-DD67-4826-95B3-3A92B354761F Q37824712-33884090-1CD5-4BAB-B613-DA76B8D98FC5 Q37893664-2F26A61C-7C00-4D0E-86AC-6925C1FD10A3 Q38071321-358FB5AC-847E-4F95-A183-1CE4FA632D2C Q38096798-CC45B735-0D30-4FD8-802F-C326DA01EC4D Q38241761-2B8370CF-9A4F-479D-8E35-97C7E7BDE79C Q38537883-3CE98C37-99FA-4420-9E92-CECF1E972AFF Q38710509-48C89E18-92EC-47B7-8883-60604EA89787 Q38760822-B8CD2858-6E1B-48EE-A8A6-30778D9D4377 Q38835113-5E8D00E1-9CFC-4E14-A88D-BB05EF13B7B4 Q38864977-7AEA54EE-4DDE-4266-83C1-37579EB77887 Q38924713-E80E97CB-E440-486D-A2A4-2FE5AA7D2EF8 Q38974433-482B40B6-6244-40F7-8B57-5EF9363333A3 Q39112940-797133A4-6282-4D28-A598-AF2AA0382E5B Q39241897-A881E7E2-6356-4895-8795-76BDA9229D0F Q40504613-0C6D511D-1A93-4BA0-A4CC-8353052BAA72 Q41209862-01A86C1B-B7E9-41FE-9B8C-4E4AD3746706

P2860

A phase 2 study of vorinostat in acute myeloid leukemia

http://www.wikidata.org/entity/Q24643266

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

A phase 2 study of vorinostat in acute myeloid leukemia

@ast

A phase 2 study of vorinostat in acute myeloid leukemia

@en

A phase 2 study of vorinostat in acute myeloid leukemia

@nl

type

label

A phase 2 study of vorinostat in acute myeloid leukemia

@ast

A phase 2 study of vorinostat in acute myeloid leukemia

@en

A phase 2 study of vorinostat in acute myeloid leukemia

@nl

prefLabel

A phase 2 study of vorinostat in acute myeloid leukemia

@ast

A phase 2 study of vorinostat in acute myeloid leukemia

@en

A phase 2 study of vorinostat in acute myeloid leukemia

@nl

P1433

Q24643266-03167C19-E81E-41B3-B7F1-C6A3854D7D1E

P1476

Q24643266-76DE4B21-D6EB-4D68-BB16-4AC421385D07

P2093

Q24643266-0C41C82C-D279-4E46-B217-16F8D51C8C5B

Q24643266-0E953FE7-2F3F-4890-BEAF-70E76369F547

Q24643266-4C91543D-7085-4655-81E9-C5D3C0A01130

Q24643266-65E57B49-AAE2-4D66-94F7-F447A9D71A3F

Q24643266-6F199E79-9174-49A7-897E-CC17D40FB276

Q24643266-ACC55622-83AB-4758-846D-3313CAEB8905

Q24643266-BAAF1847-E0F8-4C5E-A7A9-D337EFD5C4B1

Q24643266-D02192FD-2291-48CF-877C-C6D891B57D57

Q24643266-ECD66B6B-A70A-4480-8C97-B914E005CB48

P2860

Q24643266-04CAB193-4508-47BF-BB9F-E04F6A9C8922

Q24643266-0B92BA67-11AB-444E-B3F9-EA385EF8E6B0

Q24643266-12F1C711-EFE7-4950-8586-8810350DA8D0

Q24643266-171592EE-513B-499C-BF4D-A63ACF8E44BC

Q24643266-239A4DC0-149F-4594-A079-D9254E638119

Q24643266-287758B7-A98B-42C4-9622-8FAAB7101EB9

Q24643266-29E01963-3C93-403B-B169-CF181E19457B

Q24643266-2AA3454C-1228-4D20-8FD4-CF6D14586F3F

Q24643266-3A0160DC-8D7F-4BB9-9F17-7E09A88C5DD5

Q24643266-3B0DEBEE-D279-42C6-9F2F-5C014D2FC6F5

P304

Q24643266-4AD00445-8EE8-496C-A076-46A9708D59BE

P31

Q24643266-C5BA9D0D-FFFC-4DD2-8E72-47CB3D447D88

P356

Q24643266-F8104CBF-943E-4209-BCB1-B00FBA1B77CE

P407

Q24643266-499381E4-0319-409F-9940-384F413D3771

P433

Q24643266-4D4FBA11-0342-4232-B38C-35A9933B191E

P478

Q24643266-7BD9D0C3-2925-4891-9A96-A3988D59BD93

P50

Q24643266-D6D3CBCE-A11A-4265-8E00-7A85E51922F9

P577

Q24643266-9F742FBA-0321-4F46-924C-C51502145534

P5875

Q24643266-F2B7B391-602C-45BA-8651-23D1F6CF5948

P698

Q24643266-5B9934BC-8B32-4964-BAEF-C2679B083AEA

P921

Q24643266-B5ABC6FC-FB70-41C9-B2EE-076ECEE14DAC

P932

Q24643266-86A5AA20-8627-4F37-96D0-70B6DEC48F89

P356

HAEMATOL.2009.009217

P1433

P1476

A phase 2 study of vorinostat in acute myeloid leukemia

@en

P2093

Eric W Schaefer

http://www.w3.org/2001/XMLSchema#string

Igor Espinoza-Delgado

http://www.w3.org/2001/XMLSchema#string

James Slack

http://www.w3.org/2001/XMLSchema#string

John F DiPersio

http://www.w3.org/2001/XMLSchema#string

Kristina Laumann

http://www.w3.org/2001/XMLSchema#string

Mark Juckett

http://www.w3.org/2001/XMLSchema#string

Steven D Gore

http://www.w3.org/2001/XMLSchema#string

Vivek Roy

http://www.w3.org/2001/XMLSchema#string

Wenting Wu

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia

Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth.

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

The fundamental role of epigenetic events in cancer

Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission

A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

P304

1375-82

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2009.009217

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P50

Arturo Loaiza-Bonilla

P577

2009-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26860706

http://www.w3.org/2001/XMLSchema#string

P698

19794082

http://www.w3.org/2001/XMLSchema#string

P921

P932

2754953

http://www.w3.org/2001/XMLSchema#string